3.6kg of heroin seized in drug raids, 139 people arrested
Of the 139 arrested, the youngest was a 14-year-old student for suspected drug use.
CNB officers conducted raids from May 18 to May 30, covering areas such as Ang Mo Kio, Boon Keng, Bukit Merah, Jurong and Sengkang.
During the raids, more than S$626,700 (US$486,000) worth of drugs were seized. Besides the heroin, another 2.7kg of cannabis, 1.3kg of Ice, 155g of Ecstasy, 26g of cocaine and more than 200 Erimin-5 were found.
Officers also discovered 49 vape devices suspected to contain tetrahydrocannabinol, a cannabinoid found in cannabis, and 22 LSD stamps.
FIVE ARRESTED IN TUAS
In the early morning of May 23, CNB launched a raid in Tuas South Avenue, acting on information it received.
Five foreign nationals – men aged between 23 and 34 – were arrested for suspected drug offences. Two of them struggled to resist arrest, and "necessary force" was used to subdue them, said CNB.
A 23-year-old man was spotted disposing of substances, including 2g of cannabis. Another man was found with Ice.
The officers also arrested a 32-year-old man after 27g of cannabis was found in a room in a "residential lodging" in the area.
HEROIN IN GEYLANG HOTEL ROOM
On May 28, CNB officers raided a hotel room in Geylang Lorong 10 and arrested a 46-year-old man for suspected drug trafficking offences.
The officers forced their way in because the man had refused to comply with orders to open the door.
More than 2.8kg of heroin was found, together with 565g of Ice, 20g of cannabis, 24g of ketamine, four Erimin-5 tablets and over S$500 in cash.
The following day, a 29-year-old man was arrested at the car park of a condominium at Tampines Street 86 for suspected drug trafficking offences.
He was escorted to his "hideout in the condominium", said CNB. Officers found more than 2kg of cannabis, 165g of Ice, 103g of ketamine, 37g of Ecstasy, 26g of cocaine and 22 LSD stamps, as well as Erimin-5 tablets and 49 vapes.
Assistant Commissioner Aaron Tang, director CNB's Intelligence Division, said: "The drugs we seized from the operation would have destroyed countless lives and families in Singapore.
"Our message is clear - those who choose to profit from selling drugs will face the full force of CNB's actions. We will hunt these drug traffickers down to keep Singapore drug-free for our communities."
Investigations into the arrested suspects are ongoing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
an hour ago
- Straits Times
Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
Sign up now: Get ST's newsletters delivered to your inbox Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. SINGAPORE – Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium -sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Mr Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Dr Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion (S$132.4 billion) in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Dr Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targeted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Dr Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Dr Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Dr Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Dr Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. Correction note: In an earlier version of the story, we referred to the company's chief scientific officer and co-founder as Mr Boyd-Kirkup. This is incorrect. His correct form of address is Dr Boyd-Kirkup.
CNA
5 hours ago
- CNA
MINDEF to recruit 3,000 personnel this year, including 1,000 specialists for classified tech roles
Singapore's Defence Ministry will step up recruitment this year, bringing in about 3,000 new personnel. Of these, 1,000 will be specialists for classified technology roles. Defence Minister Chan Chun Sing said this is aimed at strengthening the nation's defence capabilities in a "much less secure" world. He was speaking at a defence scholarship event. 82 young Singaporeans have been given Defence Ministry and Singapore Armed Forces scholarships this year. Chloe Teo speaks with two SAF scholars.
CNA
5 hours ago
- CNA
42 awarded Ministry of Home Affairs scholarships, largest cohort in more than a decade
Second Home Affairs Minister Edwin Tong said Singapore needs strong leaders in law enforcement who can make tough decisions in the country's best interests. He said they must stand firm against drug liberalisation, hate speech and public protests — woes that are threatening public safety and security in other countries. Mr Tong was speaking to 42 police and Home Team scholars, the biggest cohort in more than a decade. Noah Kong reports.
